Rallybio Corp (RLYB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150K 300K 450K Q2 '23: 0 Q3 '23: 0 Q1 '24: 0 Q2 '24: 299K Q3 '24: 299K Q4 '24: 38K Q1 '25: 212K Q2 '25: 212K Q3 '25: 212K Q4 '25: 222K Q1 '26: 212K Q2 '26: 0 Q3 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '20: -3.8M Q2 '20: -4.7M Q3 '20: -6.7M Q4 '20: -10.1M Q1 '21: -12.8M Q2 '21: -10.5M Q3 '21: -10M Q4 '21: -12.3M Q1 '22: -14.3M Q2 '22: -17.6M Q3 '22: -18.9M Q4 '22: -17.1M Q1 '23: -18.4M Q2 '23: -20.1M Q3 '23: -19.4M Q4 '23: -21.1M Q1 '24: -19.8M Q2 '24: -17M Q3 '24: -12.1M Q4 '24: -11.6M Q1 '25: -9.7M Q2 '25: -10.1M Q3 '25: -6.9M Q4 '25: -6.4M Q1 '26: -8.7M Q2 '26: -5.7M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-30M -15M 0 15M 30M 45M Q1 '20: -3.9M Q2 '20: -4.9M Q3 '20: -7.2M Q4 '20: -10.5M Q1 '21: -13.3M Q2 '21: -11.1M Q3 '21: -10.2M Q4 '21: -12.4M Q1 '22: -14.5M Q2 '22: -17.6M Q3 '22: -18.4M Q4 '22: -16.2M Q1 '23: -17.3M Q2 '23: -18.6M Q3 '23: -18.4M Q4 '23: -20.2M Q1 '24: -19M Q2 '24: -16.2M Q3 '24: -11.5M Q4 '24: -11M Q1 '25: -9.4M Q2 '25: -9.7M Q3 '25: 16M Q4 '25: -5.9M Q1 '26: -8.3M Q2 '26: 43.7M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-20M 0 20M 40M 60M Q3 '20: -5.6M Q4 '20: -7.3M Q1 '21: -11.9M Q2 '21: -12.8M Q3 '21: -10.9M Q4 '21: -9.9M Q1 '22: -13.7M Q2 '22: -13.6M Q3 '22: -14.7M Q4 '22: -15.3M Q1 '23: -18.8M Q2 '23: -13.4M Q3 '23: -16.5M Q4 '23: -11.6M Q1 '24: -15.5M Q2 '24: -10.4M Q3 '24: -13.5M Q4 '24: -9.9M Q1 '25: -10.2M Q2 '25: -8.4M Q3 '25: -6.5M Q4 '25: -4.7M Q1 '26: -8M Q2 '26: 45.9M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '20: -5.6M Q4 '20: -7.4M Q1 '21: -12M Q2 '21: -12.8M Q3 '21: -11M Q4 '21: -10M Q1 '22: -13.8M Q2 '22: -13.6M Q3 '22: -14.7M Q4 '22: -15.3M Q1 '23: -18.8M Q2 '23: -13.4M Q3 '23: -16.5M Q4 '23: -11.7M Q4 '20 Q2 '21 Q4 '21 Q2 '22 Q4 '22 Q2 '23 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '21: 22.6M Q3 '21: 27.5M Q1 '22: 30.3M Q2 '22: 30.6M Q3 '22: 30.8M Q1 '23: 40.2M Q2 '23: 40.4M Q3 '23: 40.5M Q1 '24: 40.8M Q2 '24: 44.1M Q3 '24: 44.6M Q1 '25: 5.6M Q2 '25: 44.8M Q3 '25: 45.1M Q1 '26: 5.7M Q2 '26: 5.8M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q4 '21: -1.86 Q1 '22: -1.74 Q2 '22: -1.82 Q3 '22: -2.05 Q4 '22: -2.09 Q1 '23: -2.04 Q2 '23: -1.93 Q3 '23: -1.78 Q4 '23: -1.83 Q1 '24: -1.87 Q2 '24: -1.78 Q3 '24: -1.59 Q4 '24: -10.63 Q1 '25: -11.85 Q2 '25: -11.70 Q3 '25: -11.08 Q4 '25: -1.59 Q1 '26: -1.36 Q2 '26: 6.39 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.